LALPATHLAB Stock Overview
Operates laboratories for carrying out pathological investigations in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 6/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Dr. Lal PathLabs Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹3,356.10 |
| 52 Week High | ₹3,653.95 |
| 52 Week Low | ₹1,943.70 |
| Beta | 0.30 |
| 11 Month Change | 3.70% |
| 3 Month Change | 12.10% |
| 1 Year Change | 33.62% |
| 33 Year Change | -0.81% |
| 5 Year Change | 120.87% |
| Change since IPO | 306.80% |
Recent News & Updates
Recent updates
Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Share Price Could Signal Some Risk
Oct 06
These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely
Jul 28We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve
May 21What Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) P/E Is Not Telling You
May 01Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital
Apr 13These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely
Mar 06Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next
Feb 04Subdued Growth No Barrier To Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Price
Dec 28Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?
Nov 17Dr. Lal PathLabs (NSE:LALPATHLAB) Will Be Hoping To Turn Its Returns On Capital Around
Oct 12Here's Why Dr. Lal PathLabs (NSE:LALPATHLAB) Can Manage Its Debt Responsibly
Jul 07Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital
Jun 10Dr. Lal PathLabs (NSE:LALPATHLAB) Could Be Struggling To Allocate Capital
Feb 13Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?
Dec 29Dr. Lal PathLabs (NSE:LALPATHLAB) Will Want To Turn Around Its Return Trends
Sep 21These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Reasonably Well
Sep 01Dr. Lal PathLabs (NSE:LALPATHLAB) Will Pay A Dividend Of ₹6.00
Jul 31Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital
Jun 23Does This Valuation Of Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Imply Investors Are Overpaying?
Jun 11These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely
May 25Do Dr. Lal PathLabs's (NSE:LALPATHLAB) Earnings Warrant Your Attention?
Apr 28Shareholder Returns
| LALPATHLAB | IN Healthcare | IN Market | |
|---|---|---|---|
| 7D | -4.3% | 0.3% | -0.9% |
| 1Y | 33.6% | 45.9% | 39.7% |
Return vs Industry: LALPATHLAB underperformed the Indian Healthcare industry which returned 45.1% over the past year.
Return vs Market: LALPATHLAB underperformed the Indian Market which returned 38.5% over the past year.
Price Volatility
| LALPATHLAB volatility | |
|---|---|
| LALPATHLAB Average Weekly Movement | 3.1% |
| Healthcare Industry Average Movement | 5.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.4% |
| 10% least volatile stocks in IN Market | 3.9% |
Stable Share Price: LALPATHLAB has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: LALPATHLAB's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1949 | 4,099 | Shankha Banerjee | www.lalpathlabs.com |
Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers training programs.
Dr. Lal PathLabs Limited Fundamentals Summary
| LALPATHLAB fundamental statistics | |
|---|---|
| Market cap | ₹279.60b |
| Earnings (TTM) | ₹3.82b |
| Revenue (TTM) | ₹22.88b |
73.3x
P/E Ratio12.2x
P/S RatioIs LALPATHLAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LALPATHLAB income statement (TTM) | |
|---|---|
| Revenue | ₹22.88b |
| Cost of Revenue | ₹9.66b |
| Gross Profit | ₹13.22b |
| Other Expenses | ₹9.40b |
| Earnings | ₹3.82b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 23, 2024
| Earnings per share (EPS) | 45.80 |
| Gross Margin | 57.78% |
| Net Profit Margin | 16.68% |
| Debt/Equity Ratio | 13.1% |
How did LALPATHLAB perform over the long term?
See historical performance and comparison